OneSpan Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? OneSpan Inc trades at $17.96 (market cap $652.28M), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is far larger — about 3.5× OneSpan Inc's market cap, and OneSpan Inc pays a 2.94% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| OSPN | SLS | |
|---|---|---|
Market Cap | $652.28M | $2.28B |
Volume | 590,167 | 3,128,960 |
Sector | Technology | Health |
52-Week High | $18.42 | $15.46 |
52-Week Low | $10.15 | $1.39 |
Typical Hold Time | 18 Days | — |
Enterprise Value | $621.36M | $2.15B |
Dividend Yield | 2.94% | — |
Signals from Pluang's Aura AI — not financial advice
OneSpan (OSPN) trades at $17.70, down 3.7% over 24 hours, with a bullish technical signal from moving averages and neutral oscillators. The company shows strong profitability with a 27.76% net income margin and has beaten earnings estimates for the last three quarters. Recent news highlights investor attention and a new product launch, DigipassONE, aimed at authentication modernization.
The outlook remains positive given consistent earnings beats and a strong analyst buy consensus, though risks include negative net cash flow trends and competitive pressures in the technology sector. Revenue growth is modest, but high margins and a reasonable P/E of 10 support valuation. The stock presents a value opportunity with controlled risk.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.
Read more on OSPN →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →